Laboratory of Human Carcinogenesis
The Laboratory of Human Carcinogenesis has a multifaceted research program integrating basic, translational, clinical, and population research, with a major focus on common and lethal human cancers that include tumors of the breast, colon, esophagus, liver, lung, pancreas and prostate. Our studies utilize a Precision Medicine Strategy. Our main objectives are to conduct investigations that assess: (1) Mechanisms of carcinogenesis including the cellular functions of cancer driving genes; (2) experimental approaches in biological systems for the extrapolation of carcinogenesis data and mechanisms from in vitro models and experimental animals to humans; (3) molecular integrative epidemiology of human cancer risk; and (4) cancer biomarkers of diagnosis, prognosis, and therapeutic outcome.
The laboratory consists of five sections; the Liver Carcinogenesis Section (LCS), the Molecular Genetics and Carcinogenesis Section (MGCS), the Molecular Epidemiology Section (MES), the Pancreatic Cancer Unit (PCU) and the Integrative Molecular Epidemiology Unit (IMEU). Scientifically, the emphasis is on the role of inherited or acquired host factors as important determinants of an individual's cancer susceptibility and outcomes. Our investigations of host factors include interspecies studies among laboratory animals and humans, and are multidisciplinary to include molecular and cellular biology, pathology, epidemiology and clinical investigation. The MGCS headed by Dr. Curtis Harris devotes their major efforts to precision medicine studies of lung and colon cancer, including fundamental and mechanistic studies. The LCS headed by Dr. Xin Wang focuses mainly on dissecting tumor heterogeneity of liver cancer to improve outcome among diverse populations and identifying cancer drivers through integrated genomics. The MES headed by Dr. Stefan Ambs mainly conducts integrative molecular epidemiology studies of prostate cancer and breast cancer with a special emphasis on health disparity and utilizes epidemiological and translational research strategies to identify risk factors and pathways that influence tumor development and progression. The PCU headed by Dr. Perwez Hussain conducts integrative molecular epidemiology studies of pancreatic cancer and utilizes epidemiological and translational research strategies to identify risk factors and pathways that influence tumor development and progression. The IMEU headed by Dr. Brid Ryan uses an integrative and translational approach to study the genetics and biology behind health disparities in lung cancer and the effect of environmental exposures linked to lung cancer on RNA biology.
The overall goal of LHC is to acquire knowledge that will improve cancer prevention, early detection, stratification and effective treatment.
|Position||Degree Required||Contact Name||Contact Email|
|Post-doctoral Fellow - Liver cancer research, liver biology, genetics||Ph.D. or equivalent, M.D. or equivalent||Xin Wei Wangfirstname.lastname@example.org|
|Tenure-eligible Principal Investigator - Health Disparities Program Leader||Ph.D. or equivalent, M.D. or equivalent||Lori Hollidayemail@example.com|
Learn more about CCR research advances, new discoveries and more on our news section.
The Laboratory of Human Carcinogenesis (LHC) uses a transdisciplinary research approach to investigate the molecular epidemiology of human cancer. We perform epidemiological studies of lung (Harris and Ryan), prostate (Ambs), and liver cancer (Wang). These studies are complemented by molecular pathogenesis and translational research studies that target seven different cancer sites:
- Harris (lung, colon, esophageal cancer)
- Ambs (breast, prostate cancer)
- Wang (liver cancer)
- Hussain (pancreatic cancer)
- Ryan (lung cancer)
These malignancies are leading causes of cancer-related morbidity and mortality world-wide. To date, no prevention, screening or therapeutic regimen has been proven to be effective against liver or pancreatic cancer. Moreover, not all segments of the U.S. population have equally benefited from the advances in our knowledge and treatment of cancer. Minority, immigrant, and disadvantaged populations continue to experience an excessive cancer burden due to barriers in access to health care, cultural barriers, exposure to carcinogens and pathogens, and also ancestry-related risk factors. Using our transdisciplinary research approach, the LHC is investigating the causes of cancer health disparities. One focus is the disproportionally high cancer mortality in the African American community.
- Prostate Cancer Study Protocol
- Prostate Study Cases Questionnaire
- Prostate Study Controls Questionnaire
Center for Cancer Research National Cancer Institute
- Building 37, Room 3068A
- Bethesda, MD 20892-4258